Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 43 member 2 (SLC43A2, LAT4) is a uniporter responsible for transporting neutral L-amino acids such as methionine, leucine, phenylalanine, and valine across cell membranes via facilitated diffusion, independent of sodium, chloride, or pH gradients[1][4]. It is expressed in various tissues, including the placenta, and has important roles in amino acid metabolism, cell proliferation, and survival—particularly in tumor cells where heightened SLC43A2 activity supports increased methionine metabolism and tumor growth[2]. Elevated SLC43A2 expression correlates with cancer progression and poor prognosis in some cancers, making it a potential biomarker and therapeutic target. Currently, direct druggable inhibitors are not in clinical use, but gene knockdown or metabolic restriction has been shown to suppress tumor progression in preclinical models[2].
For experimental agents: gene silencing (e.g., siRNA) leading to reduced methionine intake/metabolism in tumor cells, resulting in decreased proliferation and increased apoptosis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 43 member 2 (SLC43A2 (LAT4)).